MPSV4

MPSV4

tetravalent meningococcal polysaccharide vaccine.
References in periodicals archive ?
The eleven vaccinations include hepatitis A, hepatitis B, varicella (chickenpox), HPV, influenza, MMR, meningococcal serogroup B, meningococcal ACWY (MenACWY and MPSV4), polio, td (tetanus and diphtheria), and tdap (tetanus, diphtheria, and pertussis).
Although neither meningococcal conjugate vaccine product is licensed for use in individuals 56 years or older, ACIP recommends using one of the products for HIVinfected individuals in this age group because the only meningococcal vaccine licensed for use in adults 56 or older, meningococcal polysaccharide vaccine (MPSV4, Menomune, Sanofi Pasteur), has not been studied in patients with HIV infection.
Meningococcal polysaccharide vaccine (MPSV4, Menomune, Sanofi Pasteur) is the only licensed meningococcal vaccine for adults aged [greater than or equal to] 56 years; however, no data are available on use of MPSV4 in HIV-infected adults.
The row pertaining to "Meningococcal" vaccinations has been changed to "Meningococcal 4-valent conjugate (MenACWY) or polysaccharide (MPSV4)," in order to clarify that "there are two types of serogroup A, C, W, and Y meningococcal vaccines available for adults." Furthermore, MenB has been given its own row on the immunization schedule.
Of particular interest is the performance of the newer conjugate vaccine, MCV-4 (Menactra; Sanofi Pasteur, Swiftwater, PA, USA), which gradually replaced MPSV4 in the military during 2006-2008.
(102) The additional diseases are hepatitis B, hemophilum influenza type b (Hib), varicella (chicken pox), rotavirus, human papillomavirus (HPV), hepatitis A (HAV), meningococcal vaccines (MCV4 and MPSV4), and pneumococcal conjugate (PCV7).
Two meningococcal vaccines are already available in the United States: the poly saccharide vaccine MPSV4 (Menomune, Sanofi Pasteur) and the conjugate vaccine MCV4 (Menactra, Sanofi Pasteur).
Those two vaccines are the polysaccharide vaccine MPSV4 (Menomune, Sanofi Pasteur) and the conjugate vaccine MCV4 (Menactra, Sanofi Pasteur).
* For meningococcal vaccination, the conjugate vaccine (MCV4) is preferred for adults aged 55 years or younger, while the polysaccharide vaccine (MPSV4) is recommended for adults older than 55 years.
* In Figures 1 ("Recommended adult immunization schedule, by vaccine and age group") and 2 ("Vaccines that might be indicated for adults based on medical and other indications"), the row for "Meningococcal" was retitled "Meningococcal 4-valent conjugate (MenACWY) or polysaccharide (MPSV4)" and a new row for "Meningococcal B (MenB)" was added; additional text was added in indication bars to describe reasons for alternate dosing schedules for vaccines where such designations were appropriate.
The meningococcal disease can be prevented by the following vaccines: MCV4 and MPSV4.
The other two meningococcal vaccines are available in the United States are the polysaccharide vaccine MPSV4 (Menomune, Sanofi-Pasteur) and the conjugate vaccine MCV4 (Menactra, Sanofi-Pasteur).